KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Exchange Rate Effect (2023 - 2025)

Biocryst Pharmaceuticals' Exchange Rate Effect history spans 3 years, with the latest figure at -$72000.0 for Q4 2025.

  • For Q4 2025, Exchange Rate Effect rose 94.48% year-over-year to -$72000.0; the TTM value through Dec 2025 reached $1.3 million, up 235.68%, while the annual FY2025 figure was $1.3 million, 235.68% up from the prior year.
  • Exchange Rate Effect reached -$72000.0 in Q4 2025 per BCRX's latest filing, up from -$468000.0 in the prior quarter.
  • In the past five years, Exchange Rate Effect ranged from a high of $1.4 million in Q2 2025 to a low of -$1.3 million in Q4 2024.
  • Average Exchange Rate Effect over 3 years is $58000.0, with a median of -$84000.0 recorded in 2023.
  • Peak YoY movement for Exchange Rate Effect: tumbled 349.81% in 2024, then surged 1050.35% in 2025.
  • A 3-year view of Exchange Rate Effect shows it stood at $522000.0 in 2023, then plummeted by 349.81% to -$1.3 million in 2024, then skyrocketed by 94.48% to -$72000.0 in 2025.
  • Per Business Quant, the three most recent readings for BCRX's Exchange Rate Effect are -$72000.0 (Q4 2025), -$468000.0 (Q3 2025), and $1.4 million (Q2 2025).